{"product_id":"harvard-infectious-diseases-in-adults-2025","title":"Harvard Infectious Diseases In Adults 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: infectious diseases physicians, internists, hospitalists, family physicians, pulmonologists, critical care physicians, emergency medicine physicians\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eState-of-the-Art Approaches to Prevention, Diagnosis, and Treatment of Infectious Diseases\u003c\/p\u003e\n\u003cp\u003eInfectious Diseases in Adults 2025 will be held online this year, using live streaming technology and live question and answer sessions.\u003c\/p\u003e\n\u003cp\u003eOVERVIEW\u003c\/p\u003e\n\u003ch3\u003eThis comprehensive CME program ensures attendees are current with state-of-the-art approaches to prevention, diagnosis, and treatment of infectious diseases. Updates, best practices, and new guidelines are presented by nationally recognized ID experts and master clinicians. Education is practical and results-driven:\u003c\/h3\u003e\n\u003cp\u003eOptimal decision-making in the prevention, diagnosis, and treatment of infectious diseases\u003c\/p\u003e\n\u003cp\u003eNewer antimicrobials and treatment strategies for highly resistant infections\u003c\/p\u003e\n\u003cp\u003ePrevention and treatment of infections in immunocompromised hosts\u003c\/p\u003e\n\u003cp\u003eUpdate on antifungal diagnostics and therapy\u003c\/p\u003e\n\u003cp\u003eState-of-the-art and multidisciplinary approaches to common infections\u003c\/p\u003e\n\u003cp\u003eClinical approaches to complex, rare, and “don’t-miss” infections\u003c\/p\u003e\n\u003cp\u003eNew, evolving, emerging, and re-emerging infectious diseases\u003c\/p\u003e\n\u003cp\u003eInfections in persons with substance use disorder\u003c\/p\u003e\n\u003cp\u003eWhat’s new in HIV prevention and management\u003c\/p\u003e\n\u003cp\u003eThe latest on COVID-19, including long COVID\u003c\/p\u003e\n\u003cp\u003eHighlights of the 2025 Program\u003c\/p\u003e\n\u003cp\u003eExpanded Case-Based and Problem-Solving Education\u003c\/p\u003e\n\u003ch3\u003eTreating Highly Resistant Infections, including:\u003c\/h3\u003e\n\u003cp\u003eMRSA and VISA (vancomycin-intermediate Staph aureus)\u003c\/p\u003e\n\u003cp\u003eExtended-spectrum beta-lactamase (ESBL)-producing Gram-negative rods\u003c\/p\u003e\n\u003cp\u003eCarbapenemase-producing Gram-negative rods, including NDM-1 metallo-beta-lactamase-producing organisms\u003c\/p\u003e\n\u003cp\u003eVancomycin-resistant enterococci (VRE)\u003c\/p\u003e\n\u003cp\u003eAspergillus and non-aspergillus mold infections\u003c\/p\u003e\n\u003cp\u003eCandida auris\u003c\/p\u003e\n\u003cp\u003eNontuberculous mycobacteria (NTM)\u003c\/p\u003e\n\u003cp\u003eCommon Infectious Diseases: Updates in Prevention, Diagnosis, and Treatment\u003c\/p\u003e\n\u003ch3\u003eUpdates to keep you current on new strategies, state-of-the-art practices, and the most recent guidelines to address:\u003c\/h3\u003e\n\u003cp\u003eRespiratory viral infections, including COVID-19\u003c\/p\u003e\n\u003cp\u003eNew and updated vaccines\u003c\/p\u003e\n\u003cp\u003eInfections in the expanding populations of immunocompromised hosts\u003c\/p\u003e\n\u003cp\u003eInfections in persons with substance use disorder\u003c\/p\u003e\n\u003cp\u003eInfections of travelers and foreign-born persons\u003c\/p\u003e\n\u003cp\u003eSystemic fungal infections\u003c\/p\u003e\n\u003cp\u003eNative and device-related orthopedic infections\u003c\/p\u003e\n\u003cp\u003eCentral nervous system (CNS) infections\u003c\/p\u003e\n\u003cp\u003eEar, nose, and throat (ENT) and eye infections\u003c\/p\u003e\n\u003cp\u003eSkin and soft tissue infections\u003c\/p\u003e\n\u003cp\u003eBronchiectasis and pneumonia\u003c\/p\u003e\n\u003cp\u003eHIV and its infectious and noninfectious complications\u003c\/p\u003e\n\u003cp\u003ePEP (Post-Exposure Prophylaxis) and PrEP (Pre-Exposure Prophylaxis) to prevent HIV infection\u003c\/p\u003e\n\u003cp\u003eSexually transmitted infections (STIs), including mpox and PEP for prevention of STIs\u003c\/p\u003e\n\u003cp\u003eHepatitis B and C infections\u003c\/p\u003e\n\u003cp\u003eTick- and mosquito-borne infections\u003c\/p\u003e\n\u003cp\u003eClostridioides difficile infection\u003c\/p\u003e\n\u003cp\u003eComplicated urinary tract infections\u003c\/p\u003e\n\u003cp\u003eIntra-abdominal infections\u003c\/p\u003e\n\u003cp\u003eChallenging, Rare, and Emerging Infectious Diseases\u003c\/p\u003e\n\u003ch3\u003eComprehensive updates on:\u003c\/h3\u003e\n\u003cp\u003eRare and emerging infectious diseases, including highly pathogenic avian flu and Marburg virus\u003c\/p\u003e\n\u003cp\u003eRe-emergence of vaccine-preventable diseases, including poliomyelitis\u003c\/p\u003e\n\u003cp\u003ePulmonary and extrapulmonary non-tuberculous (“atypical”) mycobacteria, including Mycobacterium abscessus\u003c\/p\u003e\n\u003cp\u003eGlobal infectious diseases of clinical importance\u003c\/p\u003e\n\u003cp\u003eClinical Decision-Making\u003c\/p\u003e\n\u003ch3\u003eHear directly from world-renowned specialists and master clinicians on their approach and decision-making criteria for:\u003c\/h3\u003e\n\u003cp\u003eSelecting the best antimicrobial and duration of treatment\u003c\/p\u003e\n\u003cp\u003eRapid detection and empiric treatment of life-threatening infectious diseases\u003c\/p\u003e\n\u003cp\u003eChoosing between inpatient and outpatient treatment, and between intravenous and oral antimicrobials\u003c\/p\u003e\n\u003cp\u003eOptimizing empiric antimicrobial therapy: what to start, and when to narrow or stop\u003c\/p\u003e\n\u003ch3\u003eOur multidisciplinary talks and workshops incorporate safety, quality, and practice improvement in infectious diseases, including:\u003c\/h3\u003e\n\u003cp\u003eAntimicrobial stewardship to prevent resistance and reduce cost\u003c\/p\u003e\n\u003cp\u003eInfection control to reduce transmission in health care settings\u003c\/p\u003e\n\u003cp\u003eEarly inpatient ID consultations to improve outcomes\u003c\/p\u003e\n\u003cp\u003eStrategies for management of infection in persons who inject drugs (PWID)\u003c\/p\u003e\n\u003cp\u003eOptimized for Remote Education\u003c\/p\u003e\n\u003cp\u003eThe 2025 program has been enhanced for distance learning. In addition to being live streamed, all session recordings will be made available to participants for online viewing for 90 days after the end of the course.\u003c\/p\u003e\n\u003cp\u003eNew in 2025\u003c\/p\u003e\n\u003ch3\u003eThe 2025 program adds coverage of:\u003c\/h3\u003e\n\u003cp\u003eVaccine updates\u003c\/p\u003e\n\u003cp\u003eThe latest on respiratory viral infections\u003c\/p\u003e\n\u003cp\u003eInfectious disease outbreaks of concern: highly pathogenic avian flu and Marburg virus\u003c\/p\u003e\n\u003cp\u003eID and critical care\u003c\/p\u003e\n\u003cp\u003eWho Should Attend\u003c\/p\u003e\n\u003ch3\u003ePhysicians, Nurse Practitioners, Physician Assistants, and Pharmacists in the fields of:\u003c\/h3\u003e\n\u003cp\u003eInfectious Diseases\u003c\/p\u003e\n\u003cp\u003eHospital Medicine\u003c\/p\u003e\n\u003cp\u003eInternal Medicine\u003c\/p\u003e\n\u003cp\u003eFamily Practice\u003c\/p\u003e\n\u003cp\u003ePulmonary and Critical Care Medicine\u003c\/p\u003e\n\u003cp\u003eEmergency Medicine\u003c\/p\u003e\n\u003cp\u003e…and others who care for patients with infectious diseases\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Schedule.pdf\u003c\/p\u003e\n\u003cp\u003e2. Uyeki Plenary will not be recorded (please read).pdf\u003c\/p\u003e\n\u003cp\u003e3. CPC Embargo (please read).pdf\u003c\/p\u003e\n\u003cp\u003eDay 1 An Antibiotic Allergy Toolkit.mp4\u003c\/p\u003e\n\u003cp\u003eDay 1 An Antibiotic Allergy Toolkit.pdf\u003c\/p\u003e\n\u003cp\u003eDay 1 Antimicrobial Stewardship.mp4\u003c\/p\u003e\n\u003cp\u003eDay 1 Antimicrobial Stewardship.pdf\u003c\/p\u003e\n\u003cp\u003eDay 1 Clostridioides difficile Infection, Including Recurrent and Refractory Disease and Novel Approaches.mp4\u003c\/p\u003e\n\u003cp\u003eDay 1 Clostridioides difficile Infection, Including Recurrent and Refractory Disease and Novel Approaches.pdf\u003c\/p\u003e\n\u003cp\u003eDay 1 Infection Control 101 for the ID Clinician.mp4\u003c\/p\u003e\n\u003cp\u003eDay 1 Infection Control 101 for the ID Clinician.pdf\u003c\/p\u003e\n\u003cp\u003eDay 1 Introduction and Road Map Infectious Diseases of Adults.mp4\u003c\/p\u003e\n\u003cp\u003eDay 1 Introduction and Road Map Infectious Diseases of Adults.pdf\u003c\/p\u003e\n\u003cp\u003eDay 1 Live Q \u0026amp; A 1.mp4\u003c\/p\u003e\n\u003cp\u003eDay 1 Live Q \u0026amp; A 2.mp4\u003c\/p\u003e\n\u003cp\u003eDay 1 Live Q \u0026amp; A 3.mp4\u003c\/p\u003e\n\u003cp\u003eDay 1 Live Q \u0026amp; A 4.mp4\u003c\/p\u003e\n\u003cp\u003eDay 1 Panel Workshop #1 Resistant Gram-Positive Infections.pdf\u003c\/p\u003e\n\u003cp\u003eDay 1 Panel Workshop #2 Resistant Gram-Negative Infections.pdf\u003c\/p\u003e\n\u003cp\u003eDay 1 Plenary Highly Pathogenic Avian Influenza Uyeki Plenary will not be recorded (please read).pdf\u003c\/p\u003e\n\u003cp\u003eDay 1 Principles of Antimicrobial Therapy.mp4\u003c\/p\u003e\n\u003cp\u003eDay 1 Principles of Antimicrobial Therapy.pdf\u003c\/p\u003e\n\u003cp\u003eDay 1 Skin and Soft Tissue Infections.mp4\u003c\/p\u003e\n\u003cp\u003eDay 1 Skin and Soft Tissue Infections.pdf\u003c\/p\u003e\n\u003cp\u003eDay 1 Update on Antifungal Diagnostics and Therapy.mp4\u003c\/p\u003e\n\u003cp\u003eDay 1 Update on Antifungal Diagnostics and Therapy.pdf\u003c\/p\u003e\n\u003cp\u003eDay 2 Bone and Joint Infections A Conceptual Framework.mp4\u003c\/p\u003e\n\u003cp\u003eDay 2 Bone and Joint Infections A Conceptual Framework.pdf\u003c\/p\u003e\n\u003cp\u003eDay 2 Encephalitis and Meningitis The Newest Guidelines and Best.mp4\u003c\/p\u003e\n\u003cp\u003eDay 2 Encephalitis and Meningitis The Newest Guidelines and Best.pdf\u003c\/p\u003e\n\u003cp\u003eDay 2 Keynote Lecture-Protecting Public Health with Vaccines Understanding Our Past, Protecting Our Future.pdf\u003c\/p\u003e\n\u003cp\u003eDay 2 Live Q \u0026amp; A 1.mp4\u003c\/p\u003e\n\u003cp\u003eDay 2 Live Q \u0026amp; A 2.mp4\u003c\/p\u003e\n\u003cp\u003eDay 2 Live Q \u0026amp; A 3.mp4\u003c\/p\u003e\n\u003cp\u003eDay 2 New and Emerging Viruses.mp4\u003c\/p\u003e\n\u003cp\u003eDay 2 New and Emerging Viruses.pdf\u003c\/p\u003e\n\u003cp\u003eDay 2 Panel Workshop #3 Native Bone Infections.mp4\u003c\/p\u003e\n\u003cp\u003eDay 2 Panel Workshop #3 Native Bone Infections.pdf\u003c\/p\u003e\n\u003cp\u003eDay 2 Panel Workshop #4 Orthopedic Device Infections Prosthetic Joint Infections.mp4\u003c\/p\u003e\n\u003cp\u003eDay 2 Panel Workshop #4 Orthopedic Device Infections Prosthetic Joint Infections.pdf\u003c\/p\u003e\n\u003cp\u003eDay 2 Staphylococcus aureus D‚j… Vu All Over Again.mp4\u003c\/p\u003e\n\u003cp\u003eDay 2 Staphylococcus aureus D‚j… Vu All Over Again.pdf\u003c\/p\u003e\n\u003cp\u003eDay 2 State-of-the-Art Diagnosis and Management of Sexually Transmitted Infections.pdf\u003c\/p\u003e\n\u003cp\u003eDay 2 Tick Talk Lyme Disease, Ehrlichia, Anaplasma, Babesia, Rickettsia, and Other Tick-Borne Infections.pdf\u003c\/p\u003e\n\u003cp\u003eDay 3 Advances in Viral Hepatitis HBV and HCV.mp4\u003c\/p\u003e\n\u003cp\u003eDay 3 Advances in Viral Hepatitis HBV and HCV.pdf\u003c\/p\u003e\n\u003cp\u003eDay 3 Critical Care ID.mp4\u003c\/p\u003e\n\u003cp\u003eDay 3 Critical Care ID.pdf\u003c\/p\u003e\n\u003cp\u003eDay 3 Endocarditis and Cardiac Device Infections.mp4\u003c\/p\u003e\n\u003cp\u003eDay 3 Endocarditis and Cardiac Device Infections.pdf\u003c\/p\u003e\n\u003cp\u003eDay 3 Live Q \u0026amp; A 1.mp4\u003c\/p\u003e\n\u003cp\u003eDay 3 Live Q \u0026amp; A 2.mp4\u003c\/p\u003e\n\u003cp\u003eDay 3 Live Q \u0026amp; A 3.mp4\u003c\/p\u003e\n\u003cp\u003eDay 3 Live Q \u0026amp; A 4.mp4\u003c\/p\u003e\n\u003cp\u003eDay 3 Panel Workshop #5 Multidisciplinary Management of Intraabdominal Infections (Including New Guidelines).mp4\u003c\/p\u003e\n\u003cp\u003eDay 3 Panel Workshop #5 Multidisciplinary Management of Intraabdominal Infections (Including New Guidelines).pdf\u003c\/p\u003e\n\u003cp\u003eDay 3 Panel Workshop #6 Challenges in Native Valve Endocarditis (Including in Persons with Substance Use Disorder).mp4\u003c\/p\u003e\n\u003cp\u003eDay 3 Panel Workshop #6 Challenges in Native Valve Endocarditis (Including in Persons with Substance Use Disorder).pdf\u003c\/p\u003e\n\u003cp\u003eDay 3 Panel Workshop #7 Multidisciplinary Management of Prosthetic Valve Endocarditis (Including in Persons with Substance Use Disorder).mp4\u003c\/p\u003e\n\u003cp\u003eDay 3 Panel Workshop #7 Multidisciplinary Management of Prosthetic Valve Endocarditis (Including in Persons with Substance Use Disorder).pdf\u003c\/p\u003e\n\u003cp\u003eDay 3 Panel Workshop #8 Multidisciplinary Management of Complex Urinary Tract Infections.mp4\u003c\/p\u003e\n\u003cp\u003eDay 3 Panel Workshop #8 Multidisciplinary Management of Complex Urinary Tract Infections.pdf\u003c\/p\u003e\n\u003cp\u003eDay 3 The Syndemic of SUD and Infection Updated Approaches for 2025.mp4\u003c\/p\u003e\n\u003cp\u003eDay 3 The Syndemic of SUD and Infection Updated Approaches for 2025.pdf\u003c\/p\u003e\n\u003cp\u003eDay 4 Flummoxing Cases in Fungal Infections.mp4\u003c\/p\u003e\n\u003cp\u003eDay 4 Flummoxing Cases in Fungal Infections.pdf\u003c\/p\u003e\n\u003cp\u003eDay 4 Infections in Hematologic Malignancies and Stem Cell Transplantation.mp4\u003c\/p\u003e\n\u003cp\u003eDay 4 Infections in Hematologic Malignancies and Stem Cell Transplantation.pdf\u003c\/p\u003e\n\u003cp\u003eDay 4 Infections Related to Solid Organ Transplant and Non-Oncologic Immunomodulatory Therapy.pdf\u003c\/p\u003e\n\u003cp\u003eDay 4 Live Q \u0026amp; A 1.mp4\u003c\/p\u003e\n\u003cp\u003eDay 4 Live Q \u0026amp; A 2.mp4\u003c\/p\u003e\n\u003cp\u003eDay 4 Live Q \u0026amp; A 3.mp4\u003c\/p\u003e\n\u003cp\u003eDay 4 Navigating New Vaccines Updates and Recommendations.mp4\u003c\/p\u003e\n\u003cp\u003eDay 4 Navigating New Vaccines Updates and Recommendations.pdf\u003c\/p\u003e\n\u003cp\u003eDay 4 Pre- and Post-Exposure Prophylaxis for HIV and STIs.pdf\u003c\/p\u003e\n\u003cp\u003eDay 4 Understanding and Addressing the Continuing Challenges in HIVAssociated Opportunistic Infections.mp4\u003c\/p\u003e\n\u003cp\u003eDay 4 Understanding and Addressing the Continuing Challenges in HIVAssociated Opportunistic Infections.pdf\u003c\/p\u003e\n\u003cp\u003eDay 4 What’s New in the Care of People with HIV in 2025.mp4\u003c\/p\u003e\n\u003cp\u003eDay 4 What’s New in the Care of People with HIV in 2025.pdf\u003c\/p\u003e\n\u003cp\u003eDay 5 Bronchiectasis, Pneumonia, and NTM Infections Anatomic and Clinical Approaches.mp4\u003c\/p\u003e\n\u003cp\u003eDay 5 Bronchiectasis, Pneumonia, and NTM Infections Anatomic and Clinical Approaches.pdf\u003c\/p\u003e\n\u003cp\u003eDay 5 Cases in Global Infectious Diseases.mp4\u003c\/p\u003e\n\u003cp\u003eDay 5 Cases in Global Infectious Diseases.pdf\u003c\/p\u003e\n\u003cp\u003eDay 5 Eye and ENT Infections What You Need to Know in 2025.mp4\u003c\/p\u003e\n\u003cp\u003eDay 5 Eye and ENT Infections What You Need to Know in 2025.pdf\u003c\/p\u003e\n\u003cp\u003eDay 5 Full Live.mp4\u003c\/p\u003e\n\u003cp\u003eDay 5 Kim – Viral Hepatitis.pdf\u003c\/p\u003e\n\u003cp\u003eDay 5 Live New England Journal of Medicine Clinicopathologic Conference (CPC) NEJM CPC Embargo (please read).pdf\u003c\/p\u003e\n\u003cp\u003eDay 5 Live New England Journal of Medicine Clinicopathologic Conference (CPC) NEJM CPC Presentation of Case – audience only.pdf\u003c\/p\u003e\n\u003cp\u003eDay 5 Panel Workshop #10 Management of Complex Nontuberculous Mycobacterial (NTM) Infection Extrapulmonary.mp4\u003c\/p\u003e\n\u003cp\u003eDay 5 Panel Workshop #10 Management of Complex Nontuberculous Mycobacterial (NTM) Infection Extrapulmonary.pdf\u003c\/p\u003e\n\u003cp\u003eDay 5 Panel Workshop #9 Management of Complex Nontuberculous Mycobacterial (NTM) Infection Pulmonary.mp4\u003c\/p\u003e\n\u003cp\u003eDay 5 Panel Workshop #9 Management of Complex Nontuberculous Mycobacterial (NTM) Infection Pulmonary.pdf\u003c\/p\u003e\n\u003cp\u003eDay 5 The Latest on Major Respiratory Viral Infections.mp4\u003c\/p\u003e\n\u003cp\u003eDay 5 The Latest on Major Respiratory Viral Infections.pdf\u003c\/p\u003e\n\u003cp\u003eDay 5 Tuberculosis Update.mp4\u003c\/p\u003e\n\u003cp\u003eDay 5 Tuberculosis Update.pdf\u003c\/p\u003e\n\u003cp\u003eHarvard CME _ Infectious Diseases in Adults.pdf\u003c\/p\u003e\n\u003cp\u003eNEJM CPC Embargo Notice.pdf\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405732532420,"sku":null,"price":97.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Harvard-Infectious-Diseases-In-Adults-2025.jpg?v=1784215452","url":"https:\/\/medicalcoursespro.com\/products\/harvard-infectious-diseases-in-adults-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}